Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782973 · ClinicalTrials.gov registry record · NA
Disease Management Platform for Heart Failure (DMP-HF)
A NA study of Heart Failure, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT04782973: Completed NA study of Heart Failure, sponsored by Massachusetts General Hospital.
NCT04782973 is a NA study of Heart Failure that has completed, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04782973, a NA study of Heart Failure, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
AMAZE™ is a disease management platform (DMP) designed to educate patients about heart failure, help engage them in healthy behaviors and assist them in taking their medications as prescribed. This study will assess whether the AMAZE™ smartphone-based application ("app") can help heart failure patients take better care of themselves after discharge from an inpatient heart failure admission at Massachusetts General Hospital (MGH). The primary objective is to demonstrate feasibility and perceived value of the AMAZE™ platform in clinical practice. The study will also explore whether the use of the AMAZE™ platform for 60 days post-discharge leads to a reduction in hospital readmission, emergency department, urgent care and unexpected ambulatory care visits. The impact of the AMAZE™ platform on participant reported quality of life outcomes and perception of overall medical care will also be examined.
Primary Outcome
Feasibility of implementing the AMAZE™ platform is assessed in terms of the number of patients who completed the study.
Conditions Studied
Interventions
- OTHER AMAZE (TM) Disease Management Platform
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2021-11-16 |
| Phase | NA |
What the finished NCT04782973 record still lists
NCT04782973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which AMAZE (TM) Disease Management Platform is the first listed.
NCT04782973 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04782973 about?
NCT04782973 is a clinical study titled "Disease Management Platform for Heart Failure (DMP-HF)". AMAZE™ is a disease management platform (DMP) designed to educate patients about heart failure, help engage them in healthy behaviors and assist them in taking their medications as prescribed. This study will assess whether the AMAZE™ smartphone-based application ("app") can help heart failure patie...
What is the current status of trial NCT04782973?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2021-03-11. Estimated completion is 2021-11-16.
What conditions does trial NCT04782973 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT04782973?
The interventions under investigation include: AMAZE (TM) Disease Management Platform (OTHER).
Who is sponsoring clinical trial NCT04782973?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782973 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04782973's enrollment target sits among peer trials
70 246th of 397 higher than 151 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI